Navigation Links
Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics

CAMBRIDGE, England, July 14, 2011 /PRNewswire/ --


Executives from O2h (Cambridge, UK) and Heptares Therapeutics (Welwyn Garden City, UK) signed an agreement to substantially increase the number of FTE chemists provided by O2h to support discovery programmes at Heptares.

Dr Miles Congreve, Head of Chemistry at Heptares said, "O2h has been a valuable partner for Heptares and we are happy to further extend our synthetic chemistry team to include a full lab unit at O2h."

O2h's 12 FTE lab units are modular, fully-customizable, well-equipped and IT-secure spaces which offer the optimum environment for highly productive, dedicated chemistry teams.

"Heptares has built some great partnerships with large biotechnology and pharma companies who recognize the strength of the Company's GPCR expertise and proprietary StaR® technology's. This is a new milestone in our on-going relationship with Heptares and we are excited to support them on their journey," said Sunil Shah, CEO, O2h.

About Heptares Therapeutics

Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs). The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases.

GPCRs represent the single most important family of drug targets in the human body, yet, due to their inherent instability when removed from cell membranes, little or no structural information about these valuable targets has been available to drive structure-based drug discovery programmes. Heptares' StaR® (Stabilised Receptor) technology enables the first-ever thermo-stabilisation of GPCRs. This breakthrough allows Heptares scientists to resolve GPCR structures and deploy structure-based drug discovery techniques to identify potent and selective drug candidates to previously undruggable targets.

Heptares has raised more than $40 million from leading venture investors, Clarus Ventures, MVM Life Science Partners, Novartis Option Fund and Takeda Ventures, and has formed partnerships with AstraZeneca, Shire, Takeda and Novartis. For additional information, please visit:

About O2h, a Piramal Group Company

O2h is the discovery services arm of Piramal Pharma Solutions Ltd, a top 10 global CRAMS group, offering a unique full-service partnership at every stage of the pharma life-cycle. Piramal Pharma Solutions employs 2,500 people across 9 specialist sites in North America, UK and India. The Piramal group has a 140 year history and is publicly listed company (BSE: PIRAMALHE).

O2h's 200 employees work within its project management office in Cambridge, UK and its operations in Ahmedabad India. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan.O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based medicinal, synthetic chemistry, and process chemistry as well as in vitro biology services. Further information on O2h can be found at

Contact information:
Dr Ekta Ahuja
23 Cambridge Science Park

SOURCE Oxygen Healthcare Ltd (O2h)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients
2. Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract
3. Medical Simulation Corporation Partners with Hutchinson Technology in Training of Healthcare Professionals on Noninvasive Tissue Oxygenation Monitoring
4. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
5. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
6. Spectros Corp. Deep-Monitoring Continuum Noninvasive Cerebral Oxygenation Sensors
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
9. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
10. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
11. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
Breaking Biology News(10 mins):